Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Abstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes.

Keywords: losartan, chronic kidney disease

Losartan was first Food and Drug Administration (FDA) approved in 1995 as an antihypertensive and is scheduled for generic release in April 2010.1 During the past 15 years, there has been great progress in understanding the effects of angiotensin II (AII) in the kidney and the benefits of blockade of AII at the AT1 receptor. Although losartan is now one of many angiotensin receptor blockers (ARBs), it was the first clinically used and has significantly contributed to both the physiologic understanding of AII and the clinical benefit of AII blockade. This review will present the renal effects of AT1 receptor blockade and the clinical benefits, which have been seen with losartan. It is understood that many of the effects of losartan are a class effect; however, there are 2 effects that are novel to losartan: uricosuria and effects on thrombosis. Many articles have been written about losartan; in fact, a Medline search for “losartan” returned 6,396 articles, “losartan and the kidney” 1,419, “losartan and hypertension” 2,596, and “losartan and chronic kidney disease” 262. It would be impossible to detail results of all of these. Instead an overview of the benefits of losartan is presented. Because vascular disease is a major morbidity and mortality for kidney disease patients, important outcome findings with congestive heart failure and stroke prevention are also included. Although many would consider losartan the weakest of the class, it has no doubt lead to impressive findings and important outcomes.

Pharmacokinetics and FDA approval

Losartan is a nonpeptide molecule, which is a competitive antagonist with selective binding to AT1 receptors. Losartan has an oral bioavailability of 33% and has significant first-pass
metabolism using the cytochrome P450 system. Specifically, the cytochrome P450 enzymes, CYP2C9 and CYP3A4, are involved with the biotransformation to the active metabolites that are 10–40 times more potent by weight than the parent molecule losartan. The metabolites appear to be a reversible, noncompetitive inhibitor of the AT1 receptor. Elimination of losartan is approximately 40% in urine and 60% in feces. Losartan and its metabolites are highly protein bound, mainly to albumin, but other plasma proteins bind them leaving only 1.3% and 0.2% free, respectively. The half-life of losartan is 2 hours with the terminal half-life of the metabolites being longer at 6–9 hours. When dosed twice a day, its blood pressure lowering is equivalent to other ARBs given once a day.

Losartan has FDA approval for the treatment of hypertension either alone or in combination with other antihypertensives, including diuretics. In patients with both hypertension and left ventricular hypertrophy (LVH), it is indicated to reduce the risk of stroke (although the benefit in black patients was not seen in the supporting trial). The third indication is for diabetic nephropathy in patients with type 2 diabetes with an elevated serum creatinine and proteinuria in order to reduce the occurrence of doubling of serum creatinine or end-stage renal disease. Although these are the FDA-approved indications for the clinical use of losartan, as discussed below, the benefit of losartan has been tested in multiple other settings.

Effects of losartan on the kidney

AT1 plays a significant role in the hemodynamic, electrolyte, and fluid balance regulation of the kidneys. Xu, Mao, Liu, WU and Xu have previously carefully outlined the intrarenal renin–angiotensin–aldosterone system (RAS). In order to understand the multiple effects of losartan, it is critical to understand the local effects of the RAS system, particularly the effects of AT1 receptors. The concentration of AII is about 1,000 times higher in the kidney than in the circulation. All the key elements of the RAS system have been demonstrated within various portions of the kidney, and its action have shown both paracrine and autocrine regulation. The AT1 receptor has been detected in almost all parts of the nephron.

The AT1 activation of the AT1 receptor leads to upregulation of angiotensinogen, rennin, and angiotensin-converting enzyme (ACE). Thus, losartan by blocking the AT1 receptor leads to decreased intrarenal AII by blocking this upregulation. Table 1 shows the effects of losartan on the kidney.

Blocking AT1 receptors in the kidney have multiple effects that can be beneficial. For instance, AII causes contraction of mesangial cells leading to a decrease in glomerular filtration rate (GFR), which can be blocked by losartan. However, the overall effect of losartan on GFR can be variable, depending on whether the blood pressure remains in the renal autoregulatory range. If the blood pressure is within this range, losartan is associated with an increase in GFR. However, with low blood pressure, it may be associated with decreased, increased, or unchanged GFR.

In pathologic states, AT1 blockade improves the impaired autoregulation induced by chronic abnormal activation of RAS. AT1 receptor blockade has experimentally been shown to decrease renal fibrosis as AII promotes deposition of extracellular matrix in the mesangium. AT1 activation also increased TGF-β1 that activates fibroblasts and increases their transformation to myofibroblasts, which in turn leads to fibrosis. Losartan may also be able to decrease inflammation by decreasing leukocyte proliferation and blocking upregulation of adhesion molecules. Because of these renal effects, it is not surprising that outcome studies have shown a benefit to blocking AT1 receptors with losartan.

Losartan and uric acid

A unique effect of losartan (compared to other AT1 receptor blockers) is to reduce proximal tubular reabsorption of uric acid leading to increased uric acid excretion and decreased serum uric acid concentrations. The magnitude of changes in uric acid levels has been variable in studies where losartan is used as an antihypertensive. These decreases in

<table>
<thead>
<tr>
<th>Table 1 Renal effects of blocking AT1 receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal hemodynamics</td>
</tr>
<tr>
<td>Variable effect on GFR depending on blood pressure</td>
</tr>
<tr>
<td>Improved autoregulation</td>
</tr>
<tr>
<td>Renal tubular function</td>
</tr>
<tr>
<td>Proximal tubules</td>
</tr>
<tr>
<td>Reduction of sodium and fluid reabsorption</td>
</tr>
<tr>
<td>Normalizes acidification and bicarbonate reabsorption</td>
</tr>
<tr>
<td>Distal tubules</td>
</tr>
<tr>
<td>Normalizes water, electrolytes, and acid – base balance</td>
</tr>
<tr>
<td>Collecting ducts</td>
</tr>
<tr>
<td>Blocks stimulation of aquaporin 2 and urinary concentration</td>
</tr>
<tr>
<td>Glomerular permselectivity</td>
</tr>
<tr>
<td>Improves charge selectivity of the glomerular basement membrane</td>
</tr>
<tr>
<td>Decreases radical oxygen species</td>
</tr>
<tr>
<td>Protects the size selectivity of the GBM by blocking AII-induced collagen synthesis</td>
</tr>
<tr>
<td>Ameliorates podocyte destruction</td>
</tr>
<tr>
<td>Renal fibrosis</td>
</tr>
<tr>
<td>Blocks ECM deposition in the mesangium</td>
</tr>
<tr>
<td>Attenuates fibroblast proliferation and transformation</td>
</tr>
<tr>
<td>Inflammation</td>
</tr>
<tr>
<td>Blocks proliferation of leukocytes</td>
</tr>
<tr>
<td>Blocks upregulation of adhesion molecules</td>
</tr>
</tbody>
</table>

Abbreviations: ECM, extracellular matrix; GBM, glomerular basement membrane; GFR, glomerular filtration rate; AII, angiotensin II.
Uric acid levels have also been seen in patients with renal insufficiency. Interestingly, patients with end-stage renal disease on hemodialysis also had a decrease in uric acid levels even though urinary losses could not explain this.21 The clinical implication of decreasing uric acid levels as a mechanism to decrease cardiovascular risk is unknown.

Hyperuricemia is a significant post-transplant complication in patients treated with cyclosporine. Kamper and Nielsen showed that losartan treatment in hypertensive post-transplant patients decreased fractional excretion of uric acid by 17% and decreased plasma uric acid by 8%.10 In a recent study by Zhu et al19 66 Han Chinese postrenal transplant patients were enrolled at least 3 months post transplant and with stable renal function. Thirty-four were treated for 6 months with losartan 50 mg/d and 32 served as controls. Uric acid levels significantly decreased, particularly in those with hyperuricemia. It must be noted that 9 patients in the treatment group and 5 in the control group withdrew due to acute renal insufficiency, anemia, acute rejection, or poor compliance. A second finding of this study was that hematocrit levels decreased in the losartan-treated patients, particularly in those with post-transplant erythrocytosis.

**Losartan and antiplatelet action**

Losartan exerts an antiplatelet action by blockade of thromboxane A2 (TxA2) receptors.21 In the animal model using the stroke-prone spontaneously hypertensive rat, losartan has been shown to reduce platelet activation and aggregation while causing vasodilation.22,23 In this model, this was shown not to be a class effect of ARBs as candesartan and valsartan had no effect on platelet activation.23 In humans, losartan and irbesartan have demonstrated this effect, while at higher doses, valsartan and telmisartan have inhibited platelet aggregation.24–26 Candesartan does not appear to influence platelet aggregation.27 In the usual therapeutic dosing range, losartan has been shown to be effective. This effect is not seen with ACE inhibitors.

**Losartan and proteinuria**

Reduction of proteinuria is associated with stabilization of renal disease or slowing of its progression. This has been seen in both diabetic and nondiabetic nephropathy and is both dependent and independent of blood pressure lowering.28 Losartan has also been shown to decrease proteinuria in nondiabetic nephropathies. For instance, losartan at 50 mg/d significantly decreased proteinuria in a small group of patients with biopsy-proven AA amyloidosis treated for 12 months compared with control patients with similar mean arterial blood pressure.29 In a larger trial of hypertensive patients, losartan significantly decreased proteinuria more than amlodipine in patients with higher and lower baseline levels of proteinuria.30 An additional example is a reduction of proteinuria in normotensive patients with focal segmental glomerulosclerosis.31

**Losartan and renal protection**

Blood pressure reduction is associated with renal protection and slowing of progression of chronic kidney disease (CKD). Losartan lowers blood pressure alone and in combination with other antihypertensives.32,33 Blood pressure reduction is only part of the benefit of RAS blockade for renal protection. ARBs have been shown to provide antihypertensive and renoprotective effects similar to those achieved with ACE inhibitors. The Renal protection of Optimal Antiproteinuric Doses (ROAD) trial showed that titration to maximal antiproteinuric effect of benazepril or losartan beyond usual antihypertensive ranges did not show increased blood pressure reduction but was associated with a significant reduction in the risk of doubling of the serum creatinine concentration by 49% and 50%, respectively, at 3.7 years. This was associated with a decrease in end-stage renal disease (ESRD) risk by 47% with both drugs.34

There has been 1 large trial to show the outcome benefit of losartan in type 2 diabetes patients. In this trial, 1,513 individuals with a mean creatinine of 1.9 mg/dL were enrolled in the The Reduction of End Points in Type 2 Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study. During a follow-up of 3.4 years, treatment with losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 25%; P = 0.006) and ESRD (risk reduction, 28%; P = 0.002). This protection was larger than what would be expected with blood pressure reduction alone and that these benefits exceeded those attributable to measured reductions in blood pressure.35 The most significant risk factor for progression was the degree of proteinuria at baseline and at 6 months.36–38 At 6 months, losartan reduced proteinuria by 28% while the placebo was associated with a 4% increase in proteinuria.36

The combination of ACE inhibitor with ARB has been shown to have a significant benefit in reduction of proteinuria.39,40 However, these and other studies have used submaximal dosing of each drug leaving questions as to whether the addition of an ACE inhibitor to doses of an ARB, which is at maximal antiproteinuric effect (or vice versa) would be of added benefit. Unfortunately, there is insufficient evidence to show that combination treatment slows the progression of renal disease. Initially, the combination treatment of angiotensin-II receptor blocker and ACE
inhibitor in non-diabetic renal disease (COOPERATE) study was thought to show this benefit; however, due to significant questions regarding this study, it was later retracted.41

The first effective, oral, direct renin inhibitor, aliskiren, has been evaluated in combination with the first ARB. A trial of aliskerin plus losartan in type 2 diabetic nephropathy showed a greater significant reduction of 20% in proteinuria compared with losartan alone. The outcome benefit on slowing the progression of renal disease has not yet been shown.42

**Losartan and heart failure outcome trials**

Blockade of the RAS system has been shown to improve survival and hospitalizations in heart failure patients being treated with ACE inhibitors. These benefits of treating with losartan have also been evaluated. The first trial, Evaluation of Losartan in the Elderly (ELITE) compared treatment of NYHA class II–IV heart failure patients (age 65 or older) treated with captopril (up to 50 mg, 3 times a day) and losartan (up to 50 mg a day) treated for 47 weeks. The primary end point was a worsening renal function. There were no significant changes in renal function. It is important to note that the event rate was lower than anticipated, and therefore, the study may not have been powered to show a significant difference. As a secondary end point, mortality was decreased 46% in the losartan-treated patients.43 To show superiority of losartan, a second trial ELITE II enrolled 3,152 patients (age 60 or older) with NYHA class II–IV heart failure and a left ventricular ejection fraction of 40% or less. Patients were treated with either losartan 50 mg a day or captopril 50 mg 3 times a day. There were no statistical differences between the 2 treatment arms regarding the primary end points, including sudden death and the composite of mortality and hospitalizations. Losartan was better tolerated than captopril with fewer patients discontinuing prematurely owing to adverse events (not counting death).44

These 2 studies were conducted with losartan 50 mg a day. Higher doses of losartan are associated with further decrease in blood pressure, and with increases up to 150 mg of losartan, there is increasing renin levels and circulating AII.45 The Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study) was a randomized, double-blind trial of losartan of 150 mg compared with losartan of 50 mg in patients with heart failure, who were intolerant of ACE inhibitor therapy for a median follow-up of 4.7 years. The primary end point was death or admission for heart failure. With an intention to treat analysis, there was no difference in deaths, but there was a significant decrease in hospitalizations for heart failure with fewer hospitalizations with the higher dose. Renal impairment, hypotension, and hyperkalemia were also higher in the higher dose group, but there was not an increase in discontinuation rate in this group.46

**Losartan intervention for endpoint reduction trial as a look at losartan benefits**

The Losartan Intervention for Endpoint Reduction (LIFE) trial was a double-blind study of 9,193 hypertensive patients between the ages of 55 and 80, who were at high risk. The entry criteria included hypertension and LVH (determined by ECG). Participants were randomly assigned to either losartan or atenolol. Doses were increased and hydrochlorothiazide or other medications were added to obtain a target blood pressure of less than 140/90 mmHg. Both medications were started at 50 mg and titrated to 100 mg as needed. The primary end points were occurrence of cardiovascular death, myocardial infarction, or stroke, and the composite end point was any of these events. Losartan was associated with a significantly decreased incidence of the primary composite end point. This was primarily due to a decrease in fatal and nonfatal stroke. Blood pressure control was similar in the 2 groups. This stroke benefit was not seen in African Americans.47

Substudies of this outcome trial have provided a number of additional benefits of losartan therapy in this population. Findings show a benefit of losartan over atenolol in surrogate markers, as well as in clinical outcomes. For example, losartan-treated individuals had significant LVH regression48,49 and decrease in left atrial size50,51 and decreased BNP.52,53 They also had decreased platelet aggregation, decreased serum uric acid,54 improved insulin sensitivity,55 attenuated decline in HDL,56 and decreased proteinuria.57 All of these would be significant surrogate markers for improved cardiovascular risk. Clinically significant findings were decreased incidence of atrial fibrillation58 and new onset diabetes.47,59 These may help explain the positive outcome of the LIFE trial and may prove useful to patients with chronic kidney disease after further studies.58

**The economic impact of losartan**

Several studies have looked at the economic impact of treating patients with type 2 diabetes with losartan using the RENAAL trial for analysis. A cost benefit was seen after 2–2.5 years, and at 4 years of follow-up, the cost savings by averting days with ESRD was $5,300/patient (95% CI, US $950–9,600).60 A Mexican cost assessment using the RENAAL trial showed that treatment with losartan led to greater life expectancy and
lower cost. Using the LIFE trial, a Netherland’s study noted that the medication costs for atenolol was $64 lower than for losartan, but the net cost per life year gained was only $1,083, well under the cost that is usually considered worth utilizing a treatment. Losartan has been a preferred drug on most managed care medication lists, and now that it will soon be generic, the cost benefit will increase.

Conclusion
Over the past 15 years, there has been a wide variety of studies conducted with losartan. It has shown benefit in controlling hypertension, decreasing proteinuria, slowing the progression of type 2 diabetic nephropathy, and decreasing the risk of stroke in certain populations. In addition, favorable surrogate markers such as decreased platelet aggregation, decreased uric acid, decreased proteinuria, and regression of LVH have also been documented. For a first in class medication, which is touted as being a weaker angiotensin receptor blocker, it has shown remarkable outcomes. Although, pharmacokinetic differences, particularly the shorter half-life, should be kept in mind, this drug should remain an active part of our armamentarium.

Disclosures
Dr Ripley has been a consultant and speaker for AstraZeneca.

References


